Therapeutic ingenuity.
It’s in our blood.

Patients inspire our drive to develop ground-breaking medicines for life-threatening, blood-related disorders.

Following Where the Science Leads

Portola FRG is a subsidiary of , a global biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for thrombosis and other hematological indications. Portola was founded in 2003 in South San Francisco, California, and has operations in the United States and Europe.

This page is under construction.

Please direct inquiries to the European headquarters of Portola: [email protected]

Adverse events should be reported by the following email [email protected]
or by phone (Toll Free) Tel: 0800 069 8041 or (Toll) +31 20 225 4560.

As a member of EFPIA (European Federation of Pharmaceutical Industries and Associations) and vfa (Verband Forschender Arzneimittelhersteller e.V.), Portola Pharma UK Ltd. is committed to the EFPIA Code on Disclosure of Transfers of Value from Pharmaceutical Companies to Healthcare Professionals and Healthcare Organisations. The code governs disclosures of transfers of value to healthcare professionals (HCPs) and healthcare organisations (HCOs).
UK Disclosure 2019
UK Disclosure Certification June 2020


Imprint

Publisher

Portola FRG GmbH
CEO
Gerwin Winter

Registered Seat and Registration:
District Court Munich (Amtsgericht) HRB 248872

VAT Id.: DE323904667

Contact

Fraunhoferstr. 12
82152 Martinsried/Planegg
Germany

Phone: +49 89 25 00 60 -500
Fax: +49 89 25 00 60 -599

Email: [email protected]

Privacy Policy

We are pleased about your visit and the related interest in our internet presence. The protection of your personal data (short also "data") is an important concern for us and therefore of great importance. In the following we would therefore like to inform you about the collection, processing and use of your personal data when you visit our website. More